Paracetamol/Acetaminophen During Pregnancy Induces Prenatal Ductus Arteriosus Closure
-
- Odile Becquet
- Departments of Neonatology and
-
- Damien Bonnet
- M3C-Necker, Congenital and Pediatric Cardiology, Hôpital Universitaire Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France;
-
- Yves Ville
- Paris Descartes University, Paris, France;
-
- Karel Allegaert
- Intensive Care and Department of Surgery, Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, Netherlands; and
-
- Alexandre Lapillonne
- Departments of Neonatology and
書誌事項
- 公開日
- 2018-07-01
- DOI
-
- 10.1542/peds.2017-4021
- 公開者
- American Academy of Pediatrics (AAP)
この論文をさがす
説明
<jats:p>Paracetamol or acetaminophen (APAP) is commonly used as a first line treatment of pain and fever in pregnancy. In view of new evidence that reveals that APAP medication during pregnancy may be associated with impaired outcomes, safety of the use of APAP during pregnancy should be questioned. The causality between maternal APAP treatment and prenatal ductus arteriosus closure was qualified as certain by using the World Health Organization Uppsala Monitoring Center causality assessment system in a short series of 2 clinical cases. Because the fetal ductus arteriosus closure can lead to fetal loss or life-threatening cardiac failure in the newborn, the use of APAP, specifically after the sixth month of pregnancy, should be as limited as possible.</jats:p>
収録刊行物
-
- Pediatrics
-
Pediatrics 142 (1), 2018-07-01
American Academy of Pediatrics (AAP)
